

OSTEOPORE SIGNS DISTRIBUTION AGREEMENT TO ENTER THE CHINESE MARKET

Highlights:

- *Distribution Agreement signed with Kontour (Xi'an) Medical Technology Co. Ltd (Kontour), to market and sell Osteopore products within the People's Republic of China (China).*
- *Kontour is listed on the Shanghai stock exchange, and is a leading manufacturer and distributor of surgical supplies across mainland China.*
- *Kontour and Osteopore will first conduct a number of clinical trials required to achieve 'National Medical Products Administration' (NMPA) approval. NMPA approval will allow Osteopore products to be sold across all Chinese territories.*
- *Kontour have agreed to a purchase target of US\$500,000 of Osteopore products in the first year after NMPA clearance, and US\$1,000,000 in the second year.*

23 August 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce it has signed a distribution agreement with Kontour (Xi'an) Medical Technology (Kontour), to market and sell Osteopore products within the People's Republic of China (China).

Kontour is a leading manufacturer and distributor of surgical supplies across China, and is listed on the Shanghai Stock Exchange with an estimated market value of ¥3.38bn (A\$711m)¹. The Company produces neurosurgery products, titanium materials for neurosurgery, skull internal fixation repair systems, sternum fixation systems, rib fixation systems and others.

Under the terms of the exclusive four year agreement, Kontour and Osteopore will conduct a number of clinical trials to obtain the required data to achieve National Medical Products Administration (NMPA) approval. If successful, NMPA approval will allow Osteopore products to be marketed and sold across the Peoples Republic of China.

Kontour has significant experience in the Chinese regulatory process, and anticipates NMPA approval will take an estimated 24 months. The focus will be gaining clearance for Osteopore's craniofacial (Neurosurgery) products, with Kontour agreeing to make every reasonable endeavour to purchase a minimum US\$500,000 of Osteopore products in the first year after NMPA clearance, and US\$1,000,000 in the second year.

China is a significant and high priority market for Osteopore, and Kontour was selected due to their impressive nation-wide network of hospitals and surgeons. Osteopore products are also complementary to Kontour's current neurosurgical plates and screws, and could potentially help their customers improve patient outcomes and lower complication rates during and after surgery.

In December 2021, Osteopore products were registered with Hong Kong's Medical Device Control System ("MDACS"), allowing Osteopore and Kontour to market its bioresorbable implants in the Greater Bay area, and provide implants to hospitals under special access needs. According to Wikipedia, the Greater Bay Area has a total population of approximately 71.2 million people (5% of China's total population), and includes nine mega cities as well as two special administrative regions, Hong Kong, and Macao (Macau).

Osteopore Executive Chairman, Mark Leong said, "This is a significant step in our commercialisation strategy, as the large Chinese market will be very important to Osteopore. We are laying the necessary groundwork to enter the Chinese market and working with the right partner is essential. We are glad to begin our partnership with Kontour, starting with our craniofacial products."

Kontour General Manager, Alan Zhu said "We are excited to the new partnership with Osteopore, a global leader in regenerative solutions. The Osteopore bioresorbable implant is the first of its kind to be successfully developed and commercialized for surgical use. Their innovative implants can dissolve over time, leaving only natural healthy bone. Osteopore bioresorbable implants are perfect complementary to Kontour's neural closure product portfolio and can benefit Chinese craniotomy patients in long term."

Additional agreement details

This agreement shall commence on the 23 August 2022 and continue for a fixed term of four (4) years, subject to renewal for an additional one year period. Either party may terminate this agreement, without providing any reason, at any time by giving sixty (60) days written notice to the other party. The Agreement also contains such other terms that are standard in commercial distribution agreements of this type.

All regulatory approvals, and all costs and expenses relating to submission, obtaining and maintenance thereof, shall be at the expense of Kontour unless otherwise specified by Osteopore. All product registration, licenses, approvals and consents are to be owned by Osteopore. If any regulatory approval is not obtained on or before twenty-four (24) months after the date of this agreement, Osteopore may in its sole discretion terminate this agreement.

Any confidential information is or shall be the property of Osteopore, and shall be maintained in confidence and not used in any way by the Distributor other than as necessary to perform the Distributor's obligations, nor provided or disclosed to others without consent of Osteopore.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Kontour (Xi'an) Medical Technology Co. Ltd

Kontour (Xi'an) Medical Technology Co. Ltd manufactures and distributes surgical supplies. The company produces materials for neurosurgery products, titanium materials for neurosurgery products, skull internal fixation repair systems, sternum fixation systems, rib fixation systems and others. Kontour also operates import and export businesses.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

(1) – 3,380,000,000.00 Chinese Yuan Renminbi = 711,983,181.85 Australian Dollars. CNY = 0.210646 AUD | AUD = 4.74730 CNY. Data take from www.xe.com on 17th August 2022.